Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

Current Opinion in Pharmacology

Volumn 10, Issue 3, 2010, Pages 308-315

  Taylor, Peter C ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; FC RECEPTOR; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; METHOTREXATE; PLACEBO; PROTEIN P55; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEX FORMATION; CONCENTRATION RESPONSE; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENTERITIS; HUMAN; IMMUNOGENICITY; LOADING DRUG DOSE; LUNG SARCOIDOSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIGNAL TRANSDUCTION; UVEITIS; WEGENER GRANULOMATOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; DRUG DELIVERY SYSTEM; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952746394     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.01.005     Document Type: Review

References (59)

1. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for RA. Nat Rheumatol Rev 2009, 5:578-582.
2. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
3. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinanttransmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
4. Anolik J.H., Ravikumar R., Barnard J., Owen T., Almudevar A., Milner E.C., Miller C.H., Dutcher P.O., Hadley J.A., Sanz I. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008, 180:688-692.
5. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
6. Seow C.H., Newman A., Irwin S.P., Steinhart A.H., Silverberg M.S., Greenberg G.R. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
7. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., Antoni C., Leeb B., Elliott M.J., Woody J.N., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
8. Aikawa EN, de Carvalho JF, Artur Almeida Silva C, Bonfá E: Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. In press.
9. de Vries M.K., van der Horst-Bruinsma I.E., Nurmohamed M.T., Aarden L.A., Stapel S.O., Peters M.J., van Denderen J.C., Dijkmans B.A., Wolbink G.J. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:531-535.
10. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel SO, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ: Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis. In press.
11. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Wolbink G.J., de Vries N., Tak P.P., Dijkmans B.A., Crusius J.B., van der Horst-Bruinsma I.E. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum 2009, 60:2541-2542.
12. Palframan R., Airey M., Moore A., Vugler A., Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009, 348:36-41.
13. Tutuncu Z., Kavanaugh A., Zvaifler N., Corr M., Deutsch R., Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005, 52:2693-2696.
14. Kohno T., Tam L.T., Stevens S.R., Louie J.S. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc 2007, 12:5-8.
15. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., Brown D., Robinson M., Bourne T. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323-1332.
16. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., van Montfrans C., Hommes D.W., Peppelenbosch M.P., van Deventer S.J. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
17. Tak P.P., Taylor P.C., Breedveld F.C., Smeets T.J.M., Daha M.R., Kluin P.M., Meinders A.E., Maini R.N. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077-1081.
18. Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., Feldmann M., Maini R.N. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:38-47.
19. Rigby W.F. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?. Nat Clin Pract Rheumatol 2007, 3:227-233.
20. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.
21. Arora T., Padaki R., Liu L., Hamburger A.E., Ellison A.R., Stevens S.R., Louie J.S., Kohno T. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009, 45:124-131.
22. Santora L.C., Kaymakcalan Z., Sakorafas P., Krull I.S., Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIA core. Anal Biochem 2001, 299:119-129.
23. Suffredini A.F., Reda D., Banks S.M., Tropea M., Agosti J.M., Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995, 155:5038-5045.
24. Fisher C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., Abraham E., Schein R.M., Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996, 334:1697-1702.
25. Wee S., Pascual M., Eason J.D., Schoenfeld D.A., Phelan J., Boskovic S., Blosch C., Mohler K., Cosimi A.B. Biological effects and fate of a soluble, dimeric, 80-Kda tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy. Transplantation 1997, 63:570-577.
26. Kirchner S., Holler E., Haffner S., Andreesen R., Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signalling of membrane integrated TNF in monocytes. Cytokine 2004, 28:67-74.
27. Watts A.D., Hunt N.H., Wanigasekara Y., Bloomfield G., Wallach D., Roufogalis B.D., Chaudhri G. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J 1999, 18:2119-2126.
28. Friedmann E., Hauben E., Maylandt K., Schleeger S., Vreugde S., Lichtenthaler S.F., Kuhn P.H., Stauffer D., Rovelli G., Martoglio B. SPPL2a and SPPL2b promote intramembrane proteolysis of TNF[alpha] in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 2006, 8:843-848.
29. Harashima S.-I., Horiuchi T., Hatta N., Morita C., Higuchi M., Sawabe T., Tsukamoto H., Tahira T., Hayashi K., Fujita S., Niho Y. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 2001, 166:130-136.
30. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S.-I., Kikuchi Y., Otsuka J., Okamura S., Fujita S., Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[alpha]. Gastroenterology 2005, 128:376-392.
31. Eissner G., Kolch W., Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004, 15:353-366.
32. van Lent P.L., Blom A.B., Grevers L., Sloetjes A., van den Berg W.B. TLR-4 Induced FcγR expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: tlr4 largely regulates FcγR expression by IL-10. Ann Rheum Dis 2006, 66:334-340.
33. Mitoma H., Horiuchi T., Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 2004, 26:934-935.
34. Shen C., Assche G.V., Colpaert S., Maerte P., Geboes K., Rutgeerts P., Ceuppens J.L. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005, 21:251-258.
35. Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001, 11:372-377.
36. Peppelenbosch M.P., van Deventer S.J. T cell apoptosis and inflammatory bowel disease. Gut 2004, 53:1556-1558.
37. ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
38. Di Sabatino A., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L., Cifone M.G., Corazza G.R. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Inflamm Bowel Dis 2003, 53:70-77.
39. Smeets T.J., Kraan M.C., van Loon M.E., Tak P.P. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162.
40. Catrina A.I., Trollmo C., af Klint E., Engstrom M., Lampa J., Hermansson Y., Klareskog L., Ulfgren A.K. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72.
41. Malaviya R., Sun Y., Tan J.K., Magliocco M., Gottlieb A.B. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. J Drugs Dermatol 2006, 5:890-893.
42. Malaviya R., Sun Y., Tan J.K., Wang A., Magliocco M., Yao M., Krueger J.G., Gottlieb A.B. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 2006, 55:590-597.
43. Goedkoop A.Y., Kraan M.C., Picavet D.I., de Rie M.A., Teunissen M.B., Bos J.D., Tak P.P. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004, 63:769-773.
44. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., Sharp J.T., Ory P.A., Perdok R.J., Weinberg M.A. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289. Adalimumab effectiveness in Psoriatic Arthritis Trial Study Group.
45. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., Salonen D., Rubenstein J., Sharp J.T., Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
46. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., Zhou B., Dooley L.T., Kavanaugh A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157. IMPACT 2 Trial Investigators.
47. Baughman R.P., Lower E.E., du Bois R.M. Sarcoidosis. Lancet 2003, 36:1111-1118.
48. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
49. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., Schroeder D.R. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177-185.
50. Baughman R.P., Lower E.E., Bradley D.A., Raymond L.A., Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062-1077.
51. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., Albera C., Brutsche M., Davis G., Donohue J.F., et al. Infliximab in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174:795-802.
52. Judson M.A., Baughman R.P., Costabel U., Flavin S., Lo K.H., Kavuru M.S., Drent M. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008, 31:1189-1196.
53. Rossman M.D., Newman L.S., Baughman R.P., Teirstein A., Weinberger S.E., Miller W., Sands B.E. A double-blind, randomized-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:201-208.
54. Murphy C.C., Greiner K., Plskova J., Duncan L., Frost A., Isaacs J.D., Rebello P., Waldmann H., Hale G., Forrester J.V., Dick A.D. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory non-infectious posterior uveitis. Arch Ophthalmol 2004, 122:845-851.
55. Reiff A., Takei S., Sadeghi S., Stout A., Shaham B., Bernstein B., Gallagher K., Stout T. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411-1415.
56. Foster C.S., Tufail F., Waheed N.K., Chu D., Miserocchi E., Baltatzis S., Vredeveld C.M. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121:437-440.
57. Smith J.A., Thompson D.J., Whitcup S.M., Suhler E., Clarke G., Smith S., Robinson M., Kim J., Barron K.S. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18-23.
58. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., Symmons D.P. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
59. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Bréban M., Pallot-Prades B., Pouplin S., Sacchi A., Chichemanian R.M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60:1884-1994.